The US FDA’s push to expand oncology trial eligibility criteria includes highlighting the regulatory benefits for sponsors who pursue such strategies.
Broadening eligibility criteria to include cohorts of patient populations historically excluded from cancer trials could lead to fewer postmarketing safety...







